- Home
- CLPR vs RFL Comparison
CLPR vs RFL Comparison
Compare CLPR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- RFL
- Stock Information
- Founded
- CLPR 2015
- RFL 2017
- Country
- CLPR United States
- RFL United States
- Employees
- CLPR N/A
- RFL N/A
- Industry
- CLPR Real Estate Investment Trusts
- RFL Real Estate
- Sector
- CLPR Real Estate
- RFL Finance
- Exchange
- CLPR Nasdaq
- RFL Nasdaq
- Market Cap
- CLPR 67.0M
- RFL 54.4M
- IPO Year
- CLPR 2017
- RFL N/A
- Fundamental
- Price
- CLPR $3.70
- RFL $1.25
- Analyst Decision
- CLPR
- RFL
- Analyst Count
- CLPR 0
- RFL 0
- Target Price
- CLPR N/A
- RFL N/A
- AVG Volume (30 Days)
- CLPR 53.2K
- RFL 86.2K
- Earning Date
- CLPR 11-13-2025
- RFL 12-10-2025
- Dividend Yield
- CLPR 10.38%
- RFL N/A
- EPS Growth
- CLPR N/A
- RFL N/A
- EPS
- CLPR N/A
- RFL N/A
- Revenue
- CLPR $154,179,000.00
- RFL $917,000.00
- Revenue This Year
- CLPR N/A
- RFL N/A
- Revenue Next Year
- CLPR N/A
- RFL N/A
- P/E Ratio
- CLPR N/A
- RFL N/A
- Revenue Growth
- CLPR 5.90
- RFL 43.96
- 52 Week Low
- CLPR $3.39
- RFL $1.19
- 52 Week High
- CLPR $6.49
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- CLPR 43.07
- RFL 33.85
- Support Level
- CLPR $3.66
- RFL $1.22
- Resistance Level
- CLPR $3.86
- RFL $1.29
- Average True Range (ATR)
- CLPR 0.16
- RFL 0.06
- MACD
- CLPR -0.01
- RFL -0.01
- Stochastic Oscillator
- CLPR 29.55
- RFL 25.28
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.